Skip to main content

Table 7 Association between NuclErbB-2 expression and clinicopathological characteristics in breast cancer

From: Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer

  Total cohort
(N = 273)
MembErbB-2+
N = 40
MembErbB-2+/ER-PR-
(N = 21)
MembErbB-2-/ER+PR+
(N = 145)
  NuclErbB-2, n (%) P value NuclErbB-2, n (%) P value NuclErbB-2, n (%) P value NuclErbB-2, n (%) P value
  Negative Positive   Negative Positive   Negative Positive   Negative Positive  
Tumor size             
   ≤ 20 mm 46 (26.3) 13 (13.3) 0.012a 4 (14.8) 2 (16.7) 0.885b 2 (14.3) 1 (14.3) 1b 25 (31.6) 9 (13.8) 0.012a
   > 20 mm 129 (73.7) 85 (86.7)   23 (85.2) 10 (83.3)   12 (85.7) 6 (85.7)   54 (68.4) 56 (86.2)  
Total N (%) 175 (64.0) 98 (36.0)   27 (69.2) 12 (30.8)   14 (66.7) 7 (33.3)   79 (54.9) 65 (45.1)  
Nodal metastasis             
   Negative 82 (46.9) 33 (33.7) 0.034a 10 (35.7) 4 (33.3) 0.885b 7 (50.0) 2 (28.6) 0.642b 45 (57.0) 24 (36.4) 0.013a
   Positive 93 (53.1) 65 (66.3)   18 (64.3) 8 (66.7)   7 (50.0) 5 (71.4)   34 (43.0) 42 (63.6)  
Total N (%) 175 (64.0) 98 (36.0)   28 (70.0) 12 (30.0)   14 (66.7) 7 (33.3)   79 (54.5) 66 (45.5)  
Distant metastasis             
   M0 167 (95.4) 89 (90.8) 0.130a 27 (96.4) 9 (75.0) 0.049b 14 (100) 7 (100)   75 (94.9) 62 (93.9) 1b
   M1 8 (4.6) 9 (9.2)   1 (3.6) 3 (25.5)   - -   4 (5.1) 4 (6.1)  
Total N (%) 175 (64.0) 98 (36.0)   28 (70.0) 12 (30.0)   14 (66.7) 7 (33.3)   79 (54.5) 66 (45.5)  
Clinical stage             
   I 31 (17.7) 8 (8.2) 0.031a 4 (14.3) 2 (20.0) 0.847b 2 (14.3) 1 (14.3) 1b 18 (22.8) 4 (6.1) 0.005b
   II+III+IV 144 (82.3) 90 (91.8)   24 (85.7) 8 (80.0)   12 (85.7) 6 (85.7)   61 (77.2) 62 (93.9)  
Total N (%) 175 (64.0) 98 (36.0)   28 (73.7) 10 (26.3)   14 (66.7) 7 (33.3)   79 (54.5) 66 (45.5)  
Tumor grade             
   Well to moderately differentiatedc 121 (70.3) 57 (61.3) 0.134a 16 (59.2) 5 (45.5) 0.438a 9 (64.3) 3 (42.9) 0.397b 65 (83.3) 42 (68.9) 0.044a
   Poorly differentiated 51 (29.7) 36 (38.7)   11 (40.8) 6 (54.5)   5 (35.7) 4 (57.1)   13 (16.7) 19 (31.1)  
Total N (%) 172 (65.0) 93 (35.0)   27 (71.0) 11 (29.0)   14 (66.7) 7 (33.3)   78 (56.1) 61 (43.9)  
ERd expression             
   Negative 53 (30.6) 26 (26.8) 0.540a 14 (51.9) 8 (72.7) 0.296b 14 (100) 7 (100)   1 (1.3) 2 (3.0) 0.457b
   Positive 120 (69.4) 71 (73.2)   13 (48.1) 3 (27.3)   - -   78 (98.7) 64 (97.0)  
Total N 173 (64.0) 97 (36.0)   27 (71.0) 11 (29.0)   14 (66.7) 7 (33.3)   79 (54.5) 66 (45.5)  
PRe expression             
   Negative 82 (47.4) 43 (44.8) 0.681a 18 (67.7) 9 (81.8) 0.452b 14 (100) 7 (100)   15 (19.0) 14 (21.2) 0.739a
   Positive 91 (52.6) 54 (55.2)   9 (33.3) 2 (18.2)   - -   64 (81.0) 52 (78.8)  
Total N 173 (64.0) 97 (36.0)   27 (71.0) 11 (29.0)   14 (66.7) 7(33.3)   79 (54.5) 66 (45.5)  
  1. a χ2 Test. b Fisher's exact test c Well to moderately differentiated: tumor grade 1 + 2, poorly differentiated: tumor grade 3. d ER: estrogen receptor
  2. e PR: progesterone receptor